Menu
Back to User profile » Miss Ying Tian
Papers published by Miss Ying Tian:
A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy
Lam ST, Huang H, Fang X, Wang Z, Hong H, Ren Q, Tian Y, Lin S, Lin T
Cancer Management and Research 2020, 12:1981-1990
Published Date: 17 March 2020
Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma
Zhao YY, Tian Y, Liu L, Zhan JH, Hou X, Chen X, Zhou T, Huang Y, Zhang L
Drug Design, Development and Therapy 2018, 12:2655-2663
Published Date: 29 August 2018
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
Xue C, Tian Y, Zhang J, Zhao YY, Zhan JH, Fang WF, Zhang L
Drug Design, Development and Therapy 2016, 10:1299-1306
Published Date: 31 March 2016
Efficacy of BIBF 1120 or BIBF 1120 plus chemotherapy on nasopharyngeal carcinoma in vitro and in vivo
Xue C, Tian Y, Zhang J, Zhao Y, Zhan J, Fang W, Zhang L
Drug Design, Development and Therapy 2016, 10:1173-1180
Published Date: 15 March 2016
Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
Zhao Y, Zhang J, Tian Y, Xue C, Hu Z, Zhang L
Drug Design, Development and Therapy 2015, 9:4897-4907
Published Date: 26 August 2015
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo
Zhao YY, Tian Y, Zhang J, Xu F, Yang YP, Huang Y, Zhao HY, Zhang JW, Xue C, Lam MH, Yan L, Hu ZH, Dinglin XX, Zhang L
Drug Design, Development and Therapy 2014, 8:1827-1837
Published Date: 10 October 2014
Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients
Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, Guo Y, Huang Y, Tian Y, Xie D, Zhang L
OncoTargets and Therapy 2014, 7:1301-1310
Published Date: 16 July 2014